You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Danaher reported third-quarter core revenue growth excluding respiratory revenue of 5.5% and raised full-year 2026 adjusted diluted net EPS guidance to $8.57 to $8.62. It sees 4% to 5% core revenue growth excluding respiratory revenue for 2027.
Danaher Corporation reported third-quarter 2026 revenue of $6.6 billion, up 8.5%, net earnings of $1.2 billion and adjusted diluted EPS of $2.11, and raised full-year 2026 adjusted diluted EPS guidance to $8.57 to $8.62.
Danaher reported third-quarter revenues up 8.5% and core sales up 3.0%, with core sales excluding respiratory testing up 5.5%; nine-month operating margin rose 180 basis points to 19.8%. It acquired Masimo for approximately $9.8 billion on June 10, 2026.
Danaher appointed Daniel L. Comas and Robert M. Hershberg as directors on October 9, 2026, while Steven M. Rales and Mitchell P. Rales each waived rights to 500,000 Founder RSUs.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Danaher delivered better-than-expected third-quarter results, with core revenue excluding respiratory up 5.5%, adjusted operating margin near 29%, and adjusted EPS up 11.5%, and raised full-year 2026 adjusted EPS guidance to $8.57-$8.62. Respiratory testing remained a material drag, and full-year total core revenue growth is expected to be approximately 2.5%.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DHR
this stock
Danaher Corp
|
$165.28B | +2.6% | +8.5% | 38.4 | 1.2% |
|
TMO
Thermo Fisher Scientific Inc.
|
$261.38B | +21.9% | +14.5% | 37.2 | 1.3% |
|
IDXX
Idexx Laboratories Inc
|
$55.04B | +3.3% | +10.4% | 47.1 | 2.4% |
|
NTRA
Natera, Inc.
|
$52.75B | +70.7% | -2.8% | — | 4.1% |
|
A
Agilent Technologies, Inc.
|
$49.95B | +30.2% | +6.4% | 34.9 | 1.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Danaher Corporation reported third-quarter 2026 revenue of $6.6 billion, up 8.5%, net earnings of $1.2 billion and adjusted diluted EPS of $2.11, and raised full-year 2026 adjusted diluted EPS guidance to $8.57 to $8.62.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DHR | +0.4% | +7.5% | +42.8% | +1.2% | +2.6% |
| SPY | -0.7% | -1.3% | +2.5% | +1.5% | +12.5% |
| vs SPY | +1.1% | +8.9% | +40.3% | -0.3% | -9.8% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
